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Human Experimentation: The
Review Process in Practice
Dale H. Cowan*
Institutional peer review is now a firmly established mechanism
for the oversight and control of the use of human subjects in medical
experimentation. Dr. Cowan describes in detail the structure and
operation of two institutional review boards with which he is familiar.
The author also outlines some of the difficulties that these pro-
cedures and existing federal regulations pose for both researchers
and policymakers.
For we must not deceive ourselves, morals do not forbid
making experiments on one's neighbor or on one's self; in
everyday life men do nothing but experiment on one an-
other. Christian morals forbid only one thing, doing ill to
one's neighbor. So, among the experiments that may be
tried on man, those that can only harm are forbidden,
those that are innocent are permissible, and those that may
do good are obligatory.1
I. BACKGROUND
SINCE 1966, all research and research training grants involving
human beings and supported by the United States Public Health
Service (PHS) have been subject to peer review by local institutional
committees on human investigation. This review was mandated by
the Surgeon General for all recipients of PHS grants.2 Since the vast
majority of investigators engaged in human experimentation re-
ceived some or all of their support from the PHS, the promulgation
of the policy requiring prior review of proposed projects involving
humans was followed by the establishment of review committees in
all institutions sponsoring such activities in the United States.
The original PHS guidelines required that institutional peer re-
view "should assure an independent determination of (1) the rights
and welfare of the individual or individuals involved, (2) the ap-
* M.D. Assistant Professor of Medicine, Case Western Reserve Univer-
sity. A.B., Harvard, 1959; M.D., Harvard, 1963.
1. C. BERNARD, AN INTRODUCTION TO THE STUDY OF ExP iwmNrrAL
MEDIcME 101-02 (2d ed. H.C. Greene transl. 1949).
2. Memorandum from Surgeon General, Public Health Service, to the
Heads of Institutions, Conducting Research with Public Health Service Grants,
Feb. 8, 1966, on file at Case Western Reserve Law Review.
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propriateness of the methods used to secure informed consent, and
(3) the risks and potential medical benefits of the investigation."3
The review was to be done by a "committee. .. made up of staff
of, or consultants to, [each] institution who [were] at the same time
acquainted with the investigator under review, free to assess his judg-
ment without placing in jeopardy their own goals, and sufficiently
mature and competent to make the necessary assessment."'4 It was
considered "important that some of the members be drawn from dif-
ferent disciplines or interests that do not overlap those of the investi-
gator under review." 5
Impetus for the establishment of some guidelines for the regula-
tion of human research was initially provided by the revelations at
the Nuremberg trials of the Nazi atrocities committed in the name
of medical science during World War II. The first set of guidelines
established was the Nuremberg Code, 6 which had as its central tenet
the voluntary consent of the subject involved. The rapid expansion
of medical research after World War H required the involvement as
subjects of increasing numbers of individuals. There arose a multi-
plicity of complex moral and ethical problems requiring discussion
and clarification. In 1964, the World Medical Association issued
a code of ethics on human experimentation known as the Declaration
of Helsinki." The Declaration of Helsinki emphasized the rights of
the individual subject, the principle of informed consent, and the
concept that the "importance of ,the objective [be] in proportion to
the inherent risk to the subject." 8 Additionally the Declaration of
Helsinki drew attention to the "fundamental distinction. . . between
clinical research in which the aim is essentially therapeutic for a
patient, and clinical research the essential object of which is purely
scientific and without therapeutic value to the person subjected to
the research." The Declaration also enunciated the principles that
clinical research should be based on adequate scientific background
3. Id. at 1.
4. Id. at 2.
5. Id.
6. United States v. Brandt, 2 Trials of War Criminals Before the Nurem-
berg Military Tribunals (The Medical Case) 181-82 (Military Tribunal I,
1947).
7. World Medical Ass'n, Human Experimentation: Code of Ethics of the
World Medical Association, Declaration of Helsinki, 2 BRiT. MED. J. 177
(1964).
8. Id.
9. Id.
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and experimental design and that responsible investigators should be
"scientifically qualified persons."'10
The Declaration of Helsinki was officially endorsed by the major
organizations concerned with clinical investigation and the major
medical societies in the United States." Thus, despite some earlier
reservations on the part of university departments of medicine
regarding the value of a procedural document dealing with human
investigation and the value of review committees,' 2 the major thrust
of the PHS directive of 1966 was in accord with the announced con-
sensus of the biomedical research community. It is pertinent to add
that the Surgeon General's directive was also, in part, a response to
a new public mood regarding human experimentation. The new
public concern was based on an awareness of reported abuses of in-
dividuals such as the well-publicized episode at the Jewish Chronic
Disease Hospital in Brooklyn, wherein live cancer cells were injected
into human subjects apparently without their consent.' 3
In 1971, the PHS revised and expanded its earlier policy state-
ment regarding human experimentation.' 4 The revised policy in-
corporated comments and suggestions by representatives of grantee
and contractor institutions and reflected the experience gained from
implementation for several years of the earlier policy. The policy
is applicable to "all grants or contracts which support activities in
which subjects may be at risk."'15 An individual is considered to be
"at risk" if he may be exposed to the possibility of harm-physical,
psychological, sociological, or other-as a consequence of any ac-
tivity which goes beyond the application of those established and ac-
cepted methods necessary to meet his needs.' 6 In essence, the policy
applies to any investigative study involving humans which goes
10. Id.
11. A listing of endorsing organizations is contained in World Medical
Ass'n, Human Experimentation: Declaration of Helsinki, 65 ANNALS OF IN-
TERNAL MED. 367, 368 (1966).
12. See Welt, Reflections on the Problems of Human Experimentation, 25
CONN. Mn. 75 (1961).
13. See Langer, Human Experimentation: New York Verdict Affirms Pa-
tent's Rights, 151 SCIENCE 663 (1966); cf. Hyman v. Jewish Chronic Disease
Hosp., 15 N.Y.2d 317, 206 N.E.2d 338, 258 N.Y.S.2d 397 (1965).
14. NATIONAL INsrrUTEs OF HEALTH, PuBLIc HEALTH SERVICE, U.S.
DEP'T OF HEALTH, EDUCATION AND WELFARE, THE INSTITUTIONAL GUIDE TO
DHEW POLICY ON PRoTEcToIN OF HutAN SuBJECTs (U.S. Dep't of Health,
Education, and Welfare Pub. No. [NIH] 72-102, 1971) [hereinafter cited as
TMaE INSTrrTONAL GUmI].
15. Id. at 1.
16. Id. at 2.
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beyond currently accepted diagnostic or therapeutic procedures.
The revised basic policy, now reflected in regulations' 7 promul-
gated by the Department of Health, Education, and Welfare (HEW)
in May 1974,18 has the following essential elements: (1) The insti-
tution receiving HEW funds or accountable to HEW for funds
awarded for the support of research involving human subjects shall
be responsible for safeguarding the rights and welfare of those sub-
jects.:9 (2) All requests for grants and contracts must be reviewed
and approved by an appropriate institutional committee to assure
adequate discharge of this institutional responsibility before the
grants or contracts will be made by HEW.20  (3) The review
by the institutional committee shall determine that the rights and
the welfare of the subjects are adequately protected, 21 that the risks
to an individual are outweighted by the potential benefits to him or
by the importance of the knowledge to be gained, 22 and that in-
formed consent is to be obtained by methods that are adequate and
appropriate.23 (4) There must be continuing review of research ac-
tivity involving human subjects by the institutional committee. 24
(5) The institution must submit for HEW review, approval, and of-
ficial acceptance, an assurance of its compliance with this policy.2 5
Additionally each proposal involving human subjects must be accom-
panied by a certificate provided by the institution stating that the
proposal has been or will be reviewed in accordance with the institu-
tion's assurance.2 6 (6) Grants or contracts for research involving
17. 45 C.F.R. §§ 46.1-.22 (1974). These regulations in effect formalized
the guidelines set forth in THu INsrrUrToNAL GUIDE.
18. The Public Health Service Act has been amended by the National Re-
search Service Award Act of 1974, Pub. L. No. 94-348, 88 Stat. 342. In ac-
cordance with the new Act, the Secretary of HEW has promulgated new regu-
lations. 40 Fed. Reg. 11854 (1975).
These most recent amendments are technical in nature and were promul-
gated as this issue went to press. The amendments substitute the words "insti-
tutions" and "Institutional Review Board" for existing references to "organiza-
tions" and "committees" respectively. The amendments eliminate the incon-
sistent terminology between the National Research Service Award Act of 1974
and HEW regulations. Other changes are minor and may be found by con-
sulting 40 Fed. Reg. 11854 (1975).
19. 45 C.F.R. § 46.2(a) (1974).
20. Id.
21. Id. § 46.2(b) (2).
22. Id. § 46.2(b)(1).
23. Id. § 46.2(b)(3).
24. Id. § 46.6(b).
25. Id. § 46.4(a).
26. Id. § 46.11(a).
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human subjects will only be made to individuals who are affiliated
with or sponsored by an institution which can and does assume
responsibility for the protection of the subjects. 27  (7) No grant or
contract involving human subjects shall be made unless the proposal
for such support has been reviewed and approved by an appropriate
professional committee within the responsible component of HEW.
28
H1. THE REVIEW PROCEDURE IN PRACTICE
Within this general framework, institutions are free to devise the
policies and procedures which they determine to be applicable to the
local situation. The PHS has thus charged the local institutional
committees with the tasks of formulating policies, administering those
policies, and evaluating the consequences of the policies. The extent
and manner in which different institutions have responded to the Sur-
geon General's directive varies. 29 The manner in which Case West-
ern Reserve University (CWRU) has developed and currently im-
plements and evaluates policy on human experimentation illustrates
one approach taken in response to the PHS directive. Fundamental
to the development and implementation of policy in this area by
CWRU was and is the concept that human experimentation is a co-
operative venture between the investigator and the subject whereby
"the rights of society and the rights of individual subjects are pro-
tected at the same time that faculty investigators are privileged to
carry out the mandate to advance knowledge." 30
A. The Procedure at University Hospitals of Cleveland
After the announcement of the federal policy in 1966, CWRU
organized and identified for administrative purposes seven jurisdic-
tional areas. These areas are the School of Medicine, three affiliated
teaching hospitals (University Hospitals of Cleveland, the Veterans
27. Id. § 46.2(c).
28. Id. § 46.2(a).
29. For a review of the policy of the University of California at San Fran-
cisco, see Melmon, Grossman & Morris, Emerging Assets and Liabilities of a
Committee on Human Welfare and Experimentation, 282 NEw ENG. I. MED.
427 (1970).
30. Case Western Reserve University Council on Research Involving Hu-
man Subjects, University Policy on the Involvement of Human Participants in
Research, Training, Demonstration and Related Activities, Nov. 30, 1972, at
1 [hereinafter cited as University Policy], on file at Case Western Reserve
Law Review.
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Administration Hospital, and Cleveland Metropolitan General Hos-
pital), the School of Dentistry, the School of Nursing, and all other
schools combined (including basic, social, and behavioral sciences).
Within each area an essentially independent review group was estab-
lished. The practice of protocol review was not new to University
Hospitals. This institution had been actively reviewing protocols in-
volving human subjects since the establishment, with PHS support,
of its Clinical Research Center in 1960.
The activities of each of the independent review groups within
the University are guided by the regulations laid down by HEW3 ' and
by the policy adopted by CWRU 32 in conformity with the HEW
regulations. The policy of CWRU goes beyond the spirit and letter
of the recommendations and requirements formulated by the PHS
and is on file with the National Institutes of Health (NIH) as re-
quired by the regulations.3 3
Each review committee has approached its assigned responsibili-
ties differently. These differences have included the size and
composition of the committees, the duration of service for the mem-
bers, the frequency of meetings, the procedure for handling protocols,
and the manner of communication with project directors. Neces-
sarily, the policies, procedures, and activities of the committees have
reflected the size, interests, and diversity of the staffs of the insti-
tutions. The differences may be illustrated by a description of the
committee structure and the route a protocol travels at two of the
institutions, University Hospitals (UH) and Cleveland Metropolitan
General Hospital (CMGH). The protocols reviewed by the institu-
tional committees are not the detailed grant applications or contract
proposals that are submitted to the NIH (or other agency) for fund-
ing. Rather, they are separate protocols, which include a capsule
summary of the research project and detailed considerations of all
factors pertinent to the use of human subjects in the proposed project.
Because of its geographical proximity and unique administrative
relationship to the School of Medicine, the Clinical Review Com-
mittee of University Hospitals reviews protocols from the School of
Medicine and the School of Nursing, as well as protocols from Uni-
versity Hospitals. Initially, the Dean of the School of Medicine served
as chairman of the committee, which was comprised of the depart-
mental chairmen. Since the Dean occupied a position outside of and
31. See note 17 supra.
32. University Policy, supra note 30.
33. 45 C.F.R. § 46.7 (1974).
[Vol. 25:533
THE REVIEW PROCESS
superior to the departmental chairmen, this provided a means for
resolving differences between different departments. Because of the
burden this placed on an individual who already had a substantial
number of duties and responsibilities, it was felt appropriate after
several years to relieve the Dean of this particular task. Accord-
ingly, the Chief of Staff of UH became the chairman of the commit-
tee with the same perquisites as the Dean.
As noted, the committee initially was comprised of the chairmen
of the different departments. It was found, however, that the chair-
men were not necessarily the most knowledgeable individuals to re-
view diverse proposals and that their time commitments often pre-
vented them from devoting adequate attention to the tasks of the
committee. The chairmen were therefore permitted to designate de-
partmental representatives, subject to approval by the Chief of Staff.
The Clinical Review Committee of UH now includes a faculty mem-
ber from the Department of Pharmacology and each of the clinical
departments-including radiology, pathology, and anesthesiology-
and two representatives from the School of Nursing. A community
representative, presently the Director of Health of Cuyahoga County,
and an attorney complete the committee membership. The Secre-
tary of the Clinical Research Center serves as secretary of the com-
mittee. The tenure of each member of the committee is indefinite,
being determined primarily by the willingness of the member to serve
and the discretion of the departmental and committee chairmen.
Responsibility for the overall activity and effectiveness of the com-
mittee resides in the chairman.
All persons with appointments at CWRU are subject to the Uni-
versity regulations, which apply to those conducting human experi-
mentation whether or not research undertaken by them is supported
by the PHS.34  When an investigator proposes to undertake a re-
search project involving human subjects, he must first prepare a sum-
mary of the contemplated investigation. The summary must include
a description of the purposes of the study, the methods to be used,
the nature and number of human subjects involved (e.g., normal
controls, patients with specific diseases), the manner in which pro-
spective subjects will be solicited and selected for study, the risks
to the subjects and the potential benefits to be derived, the precau-
34. A small but very significant amount of biomedical research is funded
by private groups or corporations such as the American Cancer Society, the
American Heart Association, and local groups such as the Cleveland Kidney
Foundation.
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tions that will be taken to prevent or deal with complications result-
ing from the investigation, the manner in which informed consent
will be obtained, and copy of the consent form to be used. In ex-
periments involving the use of investigational new drugs, the manner
of procuring consent must conform to Food and Drug Administration
(FDA) policy.3 5
The proposal is first sent to a departmental committee, which re-
views the protocol before forwarding it with recommendations to the
departmental chairman for approval. The departmental review
screens out poorly conceived or inadequately documented protocols.
The responsibility for departmental action and approval lies with the
departmental chairman. After obtaining departmental approval,
any protocol having special features, such as those involving the use
of radioisotopes or experimental drugs, is forwarded to the appropri-
ate committee (e.g., Isotope Committee) for review of the special
procedures. All protocols dealing with cancer projects are reviewed
in a similar manner by the Cancer Coordinating Committee of UH.
Once a protocol has been approved by appropriate special review
committees, it is submitted -to the full Clinical Review Committee.
Each of the members of the general committee is expected to review
and familiarize himself or herself with each protocol. In addition,
each protocol is assigned to -two members of the committee who re-
view it in detail. The members responsible for the detailed review
present the protocol to the committee for discussion and outline any
deficiencies or aspects of the protocol that require clarification or re-
vision. If the committee members feel they lack the expertise to
evaluate a given protocol they may enlist the opinion of an outside
consultant. The consultant need not be a member of the staff of
University Hospitals or CWRU School of Medicine. Following
thorough discussion of the protocol, the committee may vote to ap-
prove, disapprove, or defer action on a protocol. Often further clari-
fication is needed regarding research methods to be used, the risks
or expected benefits, or the manner of obtaining informed consent.
The need for further information can be communicated either ver-
bally or in writing to the project director by the chairman of the com-
mittee, another committee member, or the secretary to the commit-
tee. If the project director wishes, he or she may request to appear
personally before the committee to answer questions or provide more
detailed explanations of the proposed study. ,It is also open to the
chairman of the committee to request that the project director discuss
35. 21 C.F.R. § 130.37 (1973).
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the project with the committee. In accordance with university
policy, all projects involving definite risks to the participants receive
final review and approval through an assembled quorum of the com-
mittee.36 In general, the chairman tries to develop a consensus for
approval. Thus, it is unlikely that the chairman will accept a proto-
col for approval if there is a closely split vote. The results of the
review are communicated to the project director, the appropriate de-
partmental chairman, and the Office of Research Administration of
the University by the chairman or his designee.
In the event an unanticipated opportunity arises to perform a
unique study and rapid approval is required, the chairman of the
committee is authorized to give administrative approval for the per-
formance of one experiment upon written request of -the investigator
and after consultations with at least two other members of the com-
mittee. The proposal must then be submitted for formal review via
the usual procedures. Further studies may not be done until ap-
proval has been given by the full committee.
From 1969 through 1972, 261 new protocols were submitted to
the Clinical Review Committee of University Hospitals. Thirty-five
percent required some revision before gaining final approval. Five
protocols were disapproved. In each case, the basis for disapproval
was an unfavorable risk-benefit ratio. ,In 1972 alone, 85 new
protocols were submitted for review. ,In addition, 47 protocols pre-
viously approved were presented for annual review as required by
HEW. 37 To accomplish this task, the general hospital committee at
UH met biweekly.
B. The Procedure at Cleveland Metropolitan General Hospital
At Cleveland Metropolitan General Hospital a Committee on In-
vestigation in Humans (CI-I) was established in 1966 by the hospi-
tal's Executive Medical Staff in accordance with the directive of the
Surgeon General. Initially the committee was composed of the
chairman of each of the clinical departments plus Pathology and
Radiology, the President of the Medical Staff, and the Medical Di-
rector of the Outpatient Clinics. As constituted, the membership of
the CIH was virtually identical with that of the Executive Medical
Staff. An additional senior physician with considerable experience
36. University Policy, supra note 30, at 5.
37. THE INSTrTTiONAL GuiDE 11. Such an annual review would be neces-
sitated by a delay in excess of 12 months between the initial proposal submis-
sion date and the actual commencement of the experiment.
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in clinical investigation was selected as chairman. In contrast to
UH, CMGH has no Chief of Staff. Also, unlike the committee at
UH, the committee at CMGH did not include a member of the
hospital administration. After being in existence several years, a
representative of the Nursing Service and an attorney from outside
the hospital (Professor of Legal Medicine, Director of the Law-
Medicine Center, CWRU) joined the committee as full members.
Within the past year a representative of the community who is not
affiliated with CWRU was appointed to the committee as mandated
by the recent regulations.38 In parallel with the situation at UH,
the seven departmental chairmen now recommend representatives
from their departments to serve on the committee. These individ-
uals are nominated by the committee and appointed by the hospital
Board of Trustees at their discretion. According to the bylaws of
CMGH, the CII is a standing committee of the Medical Executive
Committee. The Medical Executive Committee has the final re-
sponsibility for the appointment of qualified professionals to the CIH.
The responsibilities of the Chairman of the CIH and the charge to
the committee are similar to those described above for University
Hospitals.
An investigator wishing to undertake research involving humans
at CMGH must submit a written protocol to the appropriate hospital
departmental chief for approval. The protocol must contain essenti-
ally the same information as that required at UH. Similarly, al in-
vestigative studies involving humans must be submitted to the same
process whether or not they require additional inside or outside sup-
port or funding, whether supported by public or private funds. After
approval of the departmental chief has been secured, the protocol is
forwarded to the chairman of the CIH, who distributes it to the com-
mittee members. Each committee member is expected to review
each protocol thoroughly prior to the next regular meeting of the
committee. Adverse comments on points requiring clarification are
requested from the members prior to the meeting. If any are com-
municated to the chairman, he relays them to the principal investiga-
tor for immediate action prior to the committee meeting if possible.
If the chairman deems it necessary, a consultant from outside the
staff of the committee or the hospital may be employed to review
the merits of a specific protocol.
A principal investigator may, at his own request or that of the
committee, appear in person before the committee to present addi-
38. 45 C.F.R. § 46.6 (1974).
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tional information or to respond to questions. In the event a specific
protocol directly involves a member of the review committee, or if
there is a possibility of conflict of interest involving a member of
the review committee, that individual does not participate in the
committee's discussion of the protocol apart from supplying informa-
tion and responding to questions if so requested by the committee.
He or she plays no role in the decisionmaking process and must ab-
stain from voting or leave the room during the vote. The minutes
of the meeting record the fact that the member left the room or
otherwise did not vote on the protocol.
After the general discussion, the chairman informally polls the
committee members to obtain a consensus of the committee regard-
ing approval of a protocol. If no consensus for approval exists, the
committee suggests changes in the protocol and asks that it be resub-
mitted. If a consensus exists, there is a formal motion for approval.
Two votes are taken. The first vote is on the risk involved and
whether the benefit to the subject and the importance of the knowl-
edge so outweigh the risk as to warrant allowing the subject to accept
it. The second vote is for approval of the protocol. The committee
may vote approval with no amendment, approval with amendment
(requiring no further action by the committee), or conditional ap-
proval. Protocols approved conditionally must be revised by the in-
vestigator in accordance with the suggestions and requirements of the
committee. The protocol is then resubmitted to the chairman, who
is charged by the committee to ensure compliance with the recom-
mended changes.
Approval for a project on an "emergency" basis may be obtained
by an investigator upon submission of a written summary of the
protocol to the appropriate departmental chief and -to the Chairman
of the CIH. The approval given by these individuals is provisional.
A complete protocol must be submitted immediately thereafter to the
full committee for formal approval. Emergency approval ordinarily
allows performance of only one experiment and is given only for
beneficial (therapeutic) research. In such a case a special meeting
of the entire committee is convened if possible.
CMGH has a Perinatal Unit supported in part by the Public
Health Service in which investigations of special societal concern that
affect both mother and child are conducted. All studies done on
the Perinatal Unit must be approved by a separate Perinatal Scienti-
fic Review Committee. Studies which receive approval are then for-
warded to the hospital CIH where approval is required as for other
1975]
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protocols before the project can be activated.
Reviews of all approved protocols are conducted at least annually
by a subcommittee of the CIH, which contains one representative
each from the Departments of Medicine, Surgery, and Obstetrics-
Gynecology. The annual review must state: (1) whether the proto-
col is active, inactive, or discontinued; (2) any change in investiga-
tors with identification of additional or deleted investigators; (3) any
change in procedures outlined in the original protocol, with appro-
priate details; (4) the place where the study is being conducted; (5)
the type of consent (verbal or written) obtained; (6) whether a con-
sent form was obtained from each subject, and, if not, the reason
for any exceptions; (7) the location where the consent forms are
kept; (8) the names and hospital numbers of all patients studied
the previous year; (9) a brief summary of the rationale, methods
of study, and general plan of investigation as described in the original
protocol; (10) a summary of the significant results that have accrued
from the study; (11) the nature of all side effects or untoward reac-
tions that occurred, major or minor, expected or unexpected; and
(12) an estimate of the number of additional subjects to be studied
in the forthcoming year. Additionally a copy of the currently ap-
proved consent form used by the investigator must be provided to
conform with current guidelines. New regulations require that ad-
verse reactions be reported promptly.39
In 1972, 40 new protocols, 2 amendments, and 4 addenda to
active, approved protocols were submitted to the CIH at CMGH.
Seventeen required modification or resubmission after committee dis-
cussion prior to final approval. A total of 149 protocols were sub-
jected to annual review, of which 58 were reported to be completed,
inactive, or discontinued. To accomplish this task, the committee
met once each month. Five protocols were approved by mail vote.
Notification of approval is reported to the project director, the de-
partmental chief, and the Office of Research Administration of
CWVRU.
Proposals involving human subjects which emanate from a juris-
dictional area outside the School of Medicine must receive approval
by the appropriate institutional committee. After receiving local in-
stitutional approval, each grant application or contract proposal is
subject to review by the Dean of the School of Medicine (or Dentis-
try, Nursing, etc., as appropriate) or his or her designee. The Dean
39. 45 C.F.R. §§ 46.6, .7 (1974).
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does not review the protocols submitted to the institutional commit-
tees on human investigation, but rather the full grant applications
or contract proposals. The Office of the Dean -then forwards the
grant application or contract proposal to the University Office of Re-
search Administration (ORA). The Director of the ORA must cer-
tify that the proposal has the approval of the appropriate local insti-
tutional committee on human experimentation. All research projects
receiving financial support must be administered through the hospital
where the work is to be conducted or through the ORA.
In addition to certifying that a research proposal has gained the
necessary institutional approval, the ORA has two other functions.
One is to assist faculty members and members of the University ad-
ministration in the acquisition and administration of grants and con-
tracts. The other is to participate in the formulation of University
policy through membership of the director on the University Council.
C. Review at the National Level
After receiving approval by the local institution and the Uni-
versity,40 all projects involving human subjects which are submitted
to the Public Health Service for funding are again reviewed by an
appropriate study section of the National Institutes of Health.
These study sections are comprised of individuals from around the
country who have expertise in a field of biomedical research. Mem-
bers of study sections are appointed for terms of two to four years
and are primarily charged with evaluating the scientific merit of the
project proposals for which financial support is sought. Although
their primary concern is not necessarily the ethics or propriety of the
proposed research, they have a duty to review the ethical considera-
tions in each project and to disapprove any project which, in -their
estimation, lacks satisfactory ethical safeguards.
Decisions of the study sections are subject to review by the Na-
tional Advisory Councils (NAC's). Each Institute of the NIH has
one NAC whose members include both scientists and laymen from
40. It is University policy that all research proposals involving human sub-
jects which are submitted to the PHS for funding be approved by the appropri-
ate institutional committee on human investigation prior to submission to the
federal government. In general, no proposals are forwarded by the Univer-
sity's Office of Research Administration which have not received local ap-
proval. Occasionally, however, because of deadline limitations, a proposal has
been forwarded to the PHS for which approval has been sought from the local
committee but not yet received. Financial support of such proposals is not
provided by the PHS until local approval has been given.
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various geographical areas. Among the responsibilities charged to
the National Advisory Councils is that of again reviewing the ethical
considerations attending projects approved by the study sections.
Although virtually all project proposals which are unacceptable on
ethical grounds are screened out at the prior levels of review, NAC's
occasionally disapprove projects because of ethical considerations.
The NIH now has made fully active a group that reviews for ethical
considerations every protocol submitted to it involving human experi-
mentation. This review is the responsibility of the Chief of the
Institutional Relations Section of the Division of Research Grants,
NIH, HEW.
A decision by a study section or a National Advisory Council
of the National Institutes of Health that a particular project does
not comply with the guidelines of the Department of Health, Educa-
tion, and Welfare supersedes the approval given the project by the
local institutional committee. Differences of this nature may be, and
usually are, resolved by further communication between the HEW
and the local institutional committee via the Office of Research Ad-
ministration. These communications generally take the form of for-
warding to the study section or National Advisory Council informa-
tion that was provided by the project director to the local institutional
review committee, either spontaneously or in response to specific
questions, and that was not included in the protocol as written in the
grant application. They may also include copies of the minutes of
the committee concerned with the proposal and copies of com-
munications passed back and forth between the committee and the
project director.
D. Criteria Used for Evaluation of Protocols
The criteria used by the Clinical Review Committee of Univer-
sity Hospitals and the Committee on Investigation in Humans at
Cleveland Metropolitan General Hospital (as well as the other inde-
pendent review committees at CWRU) to evaluate the ethical pro-
priety of a research proposal are based on the guidelines laid down
by HEW 1.4  There are three basic criteria: (1) protection of the
rights and welfare of the subjects, (2) weighing of the risks against
the benefits, and (3) determination that informed consent is to be
obtained by methods that are adequate, appropriate, and consistent
with local regulations. In addition, the committee will demand evi-
41. THE INSTrrTIONAL GUIDE; see note 17 supra.
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dence from the investigator that proper confidentiality will be main-
tained for all data collected from each individual.
Implementation of the three criteria stated above constitutes the
greatest challenge for the committees. The precise manner in which
a given committee implements -these guidelines to assess a specific
protocol varies according to the particulars of the proposal. More-
over, the application of these criteria varies with the personal back-
grounds, experiences, and biases of the members of the review com-
mittee. Situations arise, for example, in which a specific protocol
is approved by the CIH at CMGH but not approved by the commit-
tee at UH. Attempts to resolve differences between separate com-
mittees at CWRU are made on an ad hoc basis by subcommittees
of the two parent committees meeting together. The subcommittees
try to achieve a consensus. The consensus must, however, be rati-
fied by each parent committee. In the last analysis, each committee
makes its own rules and sets its own priorities. Certain general con-
siderations are utilized by the members to establish policies and
precedents which are rational and consistent with the responsibilities
of the committees towards both the subjects and investigators.
1. Protecting the Subject-The Adversary System
To assure that the rights and welfare of the subjects are pro-
tected, the committees give consideration to the role of the individual
undertaking the research as an investigator as distinguished from his
or her role as a physician. There is a distinct contrast between the
relationship of a physician to a patient and that of an investigator
to a subject. 42 Beecher has paraphrased Ladimer in saying that "the
physician accepts patients and is mainly concerned with their wel-
fare; the investigator selects subjects (problems as well as individ-
uals) and, while responsive to the patient's interest, is bent on solving
the scientific problem. ' 43 Bondy observed that
the double role which the clinical investigator plays as both
the physician and -the scientist . . . is a very touchy point
because most of the experimental subjects come into your
hands because they are patients. . . . [Y]ou have a special
rapport which hinges on the faot that you are a .physician.
The attitude of a subject toward you is strongly conditioned
42. Blumgart, The Medical Framework for Viewing the Problem of Hu-
man Experimentation, 98 DAEDALUs 248, 255-62 (1969).
43. Beecher, Experimentation in Man, 169 J.A.M.A. 461, 465 (1959), par-
aphrasing Ladimer, Human Experimentation: Medicolegal Aspects, 257 NEw
ENG. I. MED. 18, 21 (1957).
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by the fact that you are a doctor of medicine. This frequent-
ly produces a conflict because the experiment very often re-
quires manipulations that are not properly in line with what
a physician does. The object is not to improve people
but to learn from them. . . . This is just the opposite of
-a physician's usual practice. The objectives of the experi-
ments are excellent, but the experiments themselves are
anti-medical. They are useful; they may be justified; but
the physician who is in charge of these experiments is in
a very difficult position. 44
Indeed, Guttentag suggested that the "physician-friend" and
"physician-experimenter" should be two separate individuals. 45
Recognizing that "the presence of an intelligent, informed, conscien-
tious, compassionate, responsible investigator" is a prerequisite 'for
the safeguarding of an ethical approach to experimentation,4" a lead-
ing medical journal proposed editorially that a patient advocate sys-
tem be instituted "to preserve the rights of the individual in the quest
for the right to health for society." 4t  The physician-friend, to use
Guttentag's term, or patient advocate would protect the welfare of
the subject and the physician-investigator would be responsible for
the integrity of the experiment.
In fact, this type of "adversary" system is utilized by review com-
mittees today in certain circumstances. For example, at Cleveland
Metropolitan General Hospital, all patients who are potential subjects
for one of the studies involving newborn infants or very young chil-
dren must be cared for by one or more physicians who are not en-
gaged in the experiment. These physicians are responsible solely for
the medical care of their young patients and act as advocates for their
patients vis-h-vis -the investigators. They have the authority to stop
a study or withdraw a particular patient-subject from a study if they
deem it appropriate to do so. This protection is chiefly applied to
nontherapeutic research. Similarly, in dealing with the examination
of tissues removed at surgery, experimenters are not permitted to
participate in the decisions which lead to the performance of the bi-
opsy or operation in question. These medical decisions may be made
44. Beeson, Bondy, Donnelly & Smith, Panel Discussion: Moral Issues in
Clinical Research, 36 YALE J. BIOL. & MED. 455, 467 (1964).
45. Guttentag, The Problem of Experimentation on Human Beings: The
Physician's Point of View, 117 SCIENCE 207, 210 (1953).
46. Beecher, Ethics and Clinical Research, 274 NEw ENG. J. MED. 1354,
1360 (1966).
47. Editorial, Friendly. Adversaries and Human Experimentation, 275
NEw ENG. J. MED. 785, 786 (1966).
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only by the patient's physician and only on the basis of criteria that
would ordinarily be used in the particular situation.
On the other hand, the committees have recognized that there
are situations where insistence upon an adversary system is either not
feasible or is counterproductive. Examples of the former situation
are studies, such as therapeutic trials, which will be of immediate
benefit to the patient-subject (as well as to society). In the evalua-
tion of alternative chemotherapy regimens for the treatment of spe-
cific cancers, for example, the physician supervising the administra-
tion of -the different chemotherapeutic agents and the results thereof
is often also the physician with primary responsibility for the care
of the patient. The reason for the physician's dual role is that there
is no one else with the same degree of expertise both in the care
of patients with the particular neoplasm (cancer) in question and
in the pharmacology and use of the different anticancer agents. In
this situation, greater reliance is placed on the integrity of the physi-
cian to discharge his or her responsibility -to his or her patients honor-
ably than is usually the case in projects that are without immediate
benefit to the subject.
Occasionally, cases arise where an investigator simply refuses to
allow a third party to intercede between him or her and the patient-
subjects. This may be because confidentiality between the physi-
cian-investigator and the patient-subject is essential to the perform-
ance of the study, because unpredictable availability of suitable sub-
jects precludes ready availability of appropriate patient advocates, or
because the investigator indicates that it is a matter of his or her own
honor, integrity, and judgment that the work should proceed without
outside interference. The situations are highly individualistic and
-the committees make their decisions on an individual basis.
2. The Risk-Benefit Ratio
A number of general considerations affect the manner in which
committees evaluate the risk-benefit ratio in studies involving human
subjects. The observation has been repeatedly made that whenever
a physician treats a patient he or she is, in a sense, performing an
experiment since one can never be absolutely certain what the result
of treatment will be. Freund quotes F.M. Cornford's statement:
The principle of the dangerous precedent is that you should
not do an admittedly right action for -fear that you or your
equally timid successors should not have the courage to do
right in some future time, which ex hypothesi is substantially
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different but superficially resembles the -present one. Every
public action which is not customary either is wrong or,
if it is right, is a dangerous precedent. It follows that noth-
ing should ever be done for the first time.4 8
To provide the independent institutional committees with some
guidance regarding what constitutes an experiment, the CWRU
policy statement states that an experiment includes "every project
which includes procedures that go beyond the diagnostic and thera-
peutic needs of the patient or subject or may serve as a source of
potential inconvenience, embarrassment or abridgement of rights of
privacy to a participant. ' 49 Included are "procedures that may in-
duce or result in a potentially harmful altered state or condition" such
as "surgical procedures; the removal of organs or tissues for biopsy,
transplantation, or banking; the administration of drugs or radiation;
the use of indwelling catheters or electrodes; the requirement of, or
potentiality for, strenuous physicial exertion; [and] subjection to de-
ceit"5o
All experiments involve some riskY1 A cardinal principle that
guides all committees is that the risk must be commensurate with
the benefit expected from the experiment. The heavier the risk, the
greater must be the benefit. The approach taken by committees has
gone beyond the thinking reflected in the quotation from Claude Ber-
nard at the beginning of this article, that "those [experiments] that
are innocent are permissible . . . . 52 Initially, some reviewers did
not feel it was a valid concern of review committees whether or not a
proposed project might produce useful information if the project
posed minimal or no risks to the subjects. 'Now, however, all agree
with Rutstein that a study "that could not possibly yield scientific
facts . . . is by definition unethical" and "[a] worthless study cannot
possibly benefit anyone . . . ."53 Reviewers now have a more ac-
tivist view of their role and will suggest alterations in the design of
experiments that they believe will reduce the risks or improve the
quality of the data generated.
In addition to the evaluation of the overall design of experiments,
48. Freund, Ethical Problems in Human Experimentation, 273 NEw ENG.
J. MED. 687, 688 (1965).
49. University Policy, supra note 30, at 2.
50. Id. at 2-3.
51. McCance, The Practice of Experimental Medicine, 44 PROCEEDINGS OF
ROYAL Soc'y MED. 189, 192 (1951).
52. C. BERNARD, supra note 1, at 101-02.
53. Rutstein, The Ethical Design of Human Experiments, 98 DAEDALUS
523, 524 (1969).
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criteria used to assess risk include (1) whether the experiment is the
very first one in a series or one which has been done somewhere
previously, (2) whether the investigator knows that he or she will
at all times retain control of the situation, (3) whether the investi-
gator has had experience both in the general field in which he or
she is working and with respect to the procedures to be undertaken,
and (4) whether safeguards or antidotes are available to counteract
an untoward event that might occur in -the course of the study. In
situations where the research is concerned solely with discarded hu-
man materials obtained at surgery or in the course of diagnosis or
treatment, and the use of these materials involves no possible risk
to the subject, the committees concern themselves only with the cir-
cumstances under which the materials are to be procured.
The major consideration that attends the evaluation of the bene-
fit of an experiment is whether the results will be of immediate bene-
fit to the individual subjects or whether, instead, the results are in-
tended to benefit society at large. ,In studies that may be termed
therapeutic (beneficial to the patient-subject) the review committees
assess the experimental design of the study and the state of knowl-
edge upon which the design is based. For example, in a clinical trial
in which the possible efficacy of treatment with one drug is compared
to no treatment or to an alternative drug, the investigator must sup-
ply the committee with pertinent background information indicating
(1) the current mode of therapy for the condition in question, (2)
the basis (or lack thereof) of the current therapy, and (3) the evi-
dence in support of the treatment procedures to be studied. Particu-
larly in situations where an agent is to be compared with a placebo,
the investigator must demonstrate that evidence is currently lacking
regarding -the utility of any form of specific therapy. The committee
members, armed with this information, appropriately referenced, will
then often go to the library to familiarize themselves further regard-
ing the condition to be studied and the proposed treatment regimens.
Their main concerns are that subjects in at least one of the study
groups will benefit appreciably from the treatment, that the subjects
in the other groups will be no worse off than if they were treated
by conventional means, and that the experiment is properly designed
to yield valid data.
Evaluating the benefits of experiments which are nontherapeutic,
but which are intended to advance our knowledge generally to the
benefit of mankind, is infinitely more complex. The crucial issue
here is the fundamental conflict between the rights of the individual
and the rights of society. Although this conflict has been debated
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at length in the context of medical research and human investiga-
tion,54 no ready formula exists to guide the members of a review
committee. The basis for determining the expected benefits of a
project that is not directly beneficial to the patient-subject derives
from the collective medical wisdom and experience of the committee
members. In a sense, the committees have avoided confrontation
with such global issues as the individual versus society and have
focused more narrowly on the specific medical issues that are im-
mediately pertinent to the individual proposals. The willingness of
the investigator himself to undergo ,the proposed procedure has not
generally been accepted as a measure of the benefit of the procedure
relative to the risk involved. Such willingness may be a sign of good
faith, but it is recognized that the investigator may have an obsession
with his idea or, at the least, substantial emotional and intellectual
commitment to it. Hence, he or she may not be the best person
to assess dispassionately the risks and benefits and his or her self-
experimentation may be nothing more than a zealous act.
In general, review committees have taken the position that it is
justifiable to use human subjects for nonbeneficial research if they
are satisfied that the project is scientifically wise, that the benefits
to be gained exceed the risks to any one subject, that subjects will
be fully apprised of their participation in an experiment, and that
the participant-subjects will be studied only after giving informed
consent. The involvement of human subjects in research is viewed
by the committees as a cooperative venture between investigator and
subject. Although members of the review committees at CWRU
have acknowledged the right of individuals, be they normal or pa-
tients, to volunteer for hazardous procedures where the risks may ex-
ceed the benefits, they have not sanctioned any such studies. They
are guided by and have been faithful to the one overriding principle:
primum non nocere-first of all, do not harm.
3. Informed Consent
The third criterion used to evaluate the acceptability of a pro-
posed protocol, that of the quality and manner of obtaining informed
consent, has been equally difficult to implement. Consent is viewed
as serving several functions: (1) It protects the personal integrity
and dignity of the individual; (2) it protects the individual's health
54. See, e.g., Beecher, supra note 43; Blumgart, supra note 42; Freund, su-
pra note 48; Jonas, Philosophical Reflections on Experimenting With Human
Subjects, 98 DAEDALUS 219 (1969).
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and bodily integrity;5 5 and (3) it causes the investigator to reflect
on the manner in which the experiment itself is conducted.5 6 In
their deliberations the committees have used as a reference the basic
elements of informed consent outlined by HEW:
(1) A -fair explanation of the procedures to be followed,
including an identification of those which are experimental;
(2) A description of the attendant discomforts and risks;
(3) A description of -the benefits to be expected; (4) A
disclosure of appropriate alternative procedures that would
be advantageous for the subject; (5) An offer to answer
any inquiries concerning the procedures; and (6) An in-
struction that -the subject is free to withdraw his consent
and to discontinue participation in the project or activity
at any time.5 7
This last point has been amended by many investigators, including
this writer, to include the stipulation that the investigator is also free
to terminate participation of the subject if the investigator deems it
advisable for appropriate social, ethical, medical, or other reasons.
At a minimum, however, the six basic elements of informed consent
must be listed on the consent form each prospective subject is asked
to sign. The HEW guidelines, as well as the present regulations, also
direct that the consent agreement may not contain exculpatory lang-
uage whereby the subject waives, or appears to waive, his legal rights
or releases the investigator or the sponsoring institution from liability
for negligence. 58 Indeed, exculpatory clauses in consent agreements
have been disallowed in courts of law.59
In addition to these considerations, a number of other factors are
weighed by the reviewers when they are relevant to particular proto-
cols. These include whether the research is beneficial or nonbenefi-
cial to the individual subject, the ability of the potential subjects to
comprehend the information supplied by the investigator, the physi-
cal circumstances in which solicitation for participation in -the study
will occur, and the magnitude of any inducements, financial or other-
wise, that may be used to obtain subject cooperation. The review
committees at CWRU have, until now, agreed that the signed consent
55. See Jaffe, Law as a System of Control, 98 DAEDALUS 406, 423 (1969).
56. See Freund, Legal Frameworks for Human Experimentation, 98 DAE-
DALUS 314, 323 (1969).
57. THE INSTrrUToNAL GUIDE at 7. These elements are substantially the
same elements that appear in the HEW regulations promulgated in May of
1974. 45 C.F.R. § 46.3(c) (1974).
58. 45 C.F.R. § 46.9 (1974).
59. See, e.g., Tunki v. Regents of Univ. of California, 60 Cal. 2d 92, 383
P.2d 441, 32 Cal. Rptr. 33 (1963).
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given by parents or legal guardians for the participation of their chil-
dren in medical research is acceptable provided the method for ob-
taining consent is appropriate, i.e., is in accordance with the above-
stated guidelines. There is now, however, considerable controversy
on this matter and the issue is presently unresolved, particularly with
respect to nonbeneficial research.
The committees have on occasion required that a third party,
such as a family member, be present to witness the obtaining of con-
sent, in order to provide another opinion to the subject being solic-
ited, or to ensure that the explanation provided is understood by the
subject. The extent -to which the various elements that comprise in-
formed consent enter into the equation by which the committees as-
sess the adequacy and appropriateness of the consent varies with and
is unique to each proposal. There is no all-embracing formula.
Both investigators and reviewers recognize that the definition of truly
informed consent defies description, ,that "[i]f suitably approached,
patients will accede, on the basis of trust, to about any request their
physician may make,"'60 and "[a] far more dependable safeguard
than consent is the presence of a truly responsible investigator." 61
III. PROBLEMS RELATED TO THE REVIEW PROCESS
What problems attend the implementation of the review process
for the investigator and for the review committee? The major prob-
lems from the viewpoint of -the investigator are (1) the paperwork
involved in providing adequate documentation for the safety, bene-
fits, and risks of the proposed research, (2) difficulties that may arise
in communicating effectively to a subject the nature and risks of the
study so that the subject can make an informed decision regarding
his or her participation; (3) the lack of any mechanism whereby a
decision of a review committee can be appealed; and (4) the lack
of any legal safeguards for the performance of human experimenta-
tion that has received peer review and approval by a legitimate re-
view committee.
The problem of informed consent for some investigators is based
in part on the fact that they prefer not to state explicitly what they
intend to do or why. For others, full explanation of the procedures
may directly impair the study. For example, in studies designed to
evaluate the relative efficacies of two drugs, it is often important that
60. Beecher, supra note 46, at 1355.
61. Id.
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neither the subjects nor the investigators know which drug is being
given and to whom-the so-called double-blind trial. In these situ-
ations it may not be feasible to provide the subjects with the informa-
tion they would ordinarily need to determine whether to participate.
Rather, full disclosure is made to the subject of all the possible side
effects or risks that either regimen may entail and the fact that
neither he or she nor the investigator knows which regimen will be
given. Despite these problems, the review process provides the in-
vestigator with the opportunity of having his research plans evaluated
by an impartial, disinterested group of his peers. The review com-
mittees seek to be constructive and to help the investigator and, to
the extent they do, are an advantage for the investigator. Investi-
gators have been uniformly appreciative when the interchange oc-
casioned by the review process has resulted in improvement in ex-
perimental design or an increase in the potential for obtaining deci-
sive results.
The problems that attend the review process for the review com-
mittees are multiple and complex. They have yet to be resolved and
one can do little more than list them.
(1) The local institutional committees have been charged with
the dual responsibility of both formulating and implementing policy.
They have often had little guidance in performing these roles in the
myriad diverse situations that have arisen and have had to establish
precedents where none existed previously. Simply stated, the law
is silent on these matters. In an attempt to solve this problem, -the
CWRU Faculty Senate Committee on Research and Scholarship es-
tablished a coordinating committee consisting of the chairmen of the
seven institutional review committees within CWRU. In 1971 this
group was redesignated the University Council on Research Involv-
ing Human Subjects and was charged with responsibilities to initiate
or modify policies or procedures, to communicate experience, prob-
lems or practices between the seven committees, to monitor imple-
mentation of University policy, to report periodically to the Officers
and Administration of the University on issues or problems in the
area of human experimentation and to serve as a vehicle for com-
municating with the Committee on Research and Scholarship and
with the faculty.62
(2) In almost every case, the committees have had to, maintain
a fine balance between acquiring adequate documentation for mak-
ing a decision and imposing an excessive amount of paperwork upon
62. University Policy, supra note 30, at 6.
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the investigator. The committees must balance the need to protect
the patients' rights and welfare against the privilege of the investi-
gator to undertake research. In a more general sense, the commit-
tees must balance the need to protect the individual against the man-
date that exists in medicine to improve patient care.
(3) There is an increasing volume of paperwork for the mem-
bers of the review committees. All of the members have other re-
sponsibilities for teaching, research, and patient care. As the work-
load increases, the time and commitment each member can devote
to other responsibilities is inevitably reduced.
(4) Proper evaluation of some protocols is too complex for local
institutional committees. For example, CMGH is a member of a co-
operative cancer chemotherapy group that embraces over 30 other
institutions nationwide. An increasing number of protocols devised
to evaluate treatment regimens are being introduced to determine op-
timal therapy for various neoplasms. These protocols have been de-
signed by a national committee and have received scientific approval
by the National Cancer Institute, a component of the National Insti-
tutes of Health; nevertheless, they must be approved locally before
they can be used locally. The protocols involve so many different
tumors and drugs and so many combinations of drugs and other
therapeutic modalities, many of which are still investigational, that
it is not feasible for the CIH at CMGH to make a truly informed
decision on each one. Consequently, the committee has adopted the
procedure of delegating a subcommittee to review each protocol,
chiefly to determine the adequacy of consent. The scientific merits
of each protocol are reviewed on the basis of published material and
experience. Since no one institution can have enough experience to
have compiled its own definitive data, however, cooperative multi-
institutional studies are necessary. The most complete data are
available only to a central group, which evaluates composite results
on which new protocols are based.
(5) Projects involving special groups raise special problems.
Foremost among these are projects involving children, particularly
newborn infants, and women during pregnancy. An additional prob-
lem surrounds research done on aborted fetuses and products of con-
ception. Stringent federal regulations exist which essentially prohibit
certain types of investigation, often with unfortunate and unintended
consequences. For example, FDA regulations require that the label-
ing of a drug prescribe, recommend or suggest its use only under the
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conditions for which it was tested and approved.63 Because children
are generally agreed to be incapable of giving consent and because
controversy exists whether their parents or guardians can legally give
consent for their participation in research, 64 particularly where the
research is not of therapeutic benefit to the child, investigators are
becoming progressively more reluctant to test new drugs in children.
Consequently, manufacturers indicate on the drug labels that clinical
studies have been insufficient to establish recommendations for use
in infants and children. Stated simply, one cannot use new drugs
in children unless they have been certified for use in children. But
one cannot get the new drugs certified for use in children because
it is nonbeneficial research and one cannot do nonbeneficial research
in children. Hence, either the pediatricians practice illegally or the
children become therapeutic orphans.
(6) There is no readily available mechanism for exchanging
information with review committees at other universities and no
mechanism for resolving differences between committees. Each re-
view committee builds "a body of general principles over a period
of time on a case-by-case basis."6 5 Since the viewpoints and biases
of committees may differ, the possibility exists -that two committees
might evaluate a particular protocol quite differently. The Univer-
sity Council, as mentioned above, is primarily a policy making group
and is not equipped to resolve such differences. Presently, these
problems are resolved by discussions between ad hoe subcommittees
of each parent institutional committee. The compromise agreed
upon by the subcommittees must be ratified by each parent commit-
tee. A number of suggestions have been made regarding the estab-
lishment of a clearinghouse whereby the deliberations and decisions
pertaining to difficult problems would be available for dissemination
and discussion for the purpose of achieving through dialogue some
degree of national consensus. The merits of these proposals have
been discussed by Curran. 66
(7) It is difficult to monitor compliance with decisions of the in-
stitutional review committees. The annual review is retrospective
63. 21 C.F.R. § 1.106(a)(1) (1973).
64. See Capron, Legal Considerations Affecting Clinical Pharmacological
Studies in Children, 21 CLi'mcAL REsEARcH 141-42 (1973); Chalkley, De-
veloping Guidelines, 21 CLwNcAL RESEARCH 777, 779 (1973).
65. Curran, Governmental Regulation of the Use of Human Subjects in
Medical Research: The Approach of Two Federal Agencies, 98 DARDALUS 542,
584 (1969).
66. See id. at 586.
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and does not include any provisions or mechanism for supervising
ongoing research. Consequently, there is no way to determine, for
example, whether a surgical procedure is being done for a valid diag-
nostic or therapeutic reason or simply for research purposes. Sim-
ilarly, it is not possible to ascertain in every single instance in which
drugs are being administered whether they are being administered
only for approved purposes. The logistics and manpower demands
make anything beyond initial approval and annual review impossible.
(8) The perspectives of the committees are relatively limited.
In recognition of a need to broaden the scope of the committee de-
liberations, there has been some movement to include on committees
more members from outside of medicine, including the consumer.
This has been done in part to improve the public image of human
experimentation and to reduce the suspicions of the outside world.
Inclusion of nonphysicians raises further problems, however, since,
as these individuals admit frankly, they often do not comprehend the
medical issues involved and thus are obliged to defer to the physi-
cians' judgment with respect to matters requiring scientific compe-
tence.
Two additional problems with which committees are becoming in-
creasingly concerned are those dealing with the legal status of review
and with compensation for subjects injured during participation in ex-
periments. There have been few lawsuits resulting from human ex-
perimentation,67 and thus there is little case law to guide review
committees or policymaking councils. Similarly, the legal status of
the investigator and his insurability for professional liability are
wholly undetermined. 8 This writer vividly recalls being officially in-
formed, at the start of a 2-year term as a Clinical Associate at the
NIH, that no insurance carrier would underwrite a professional lia-
bility policy protecting individuals who were engaged in clinical in-
vestigation. It is highly doubtful now whether professional liability
insurance obtained by someone engaged in the practice of medicine
would protect that individual in the event he or she undertook human
experimentation and a lawsuit were filed because of some injury al-
leged to have arisen from the research. CalabresiGO and Havig-
hurst 70' have pointed out that little attention has been paid to the
67. Jaffe, supra note 55, at 408.
68. Beecher, Human Studies, 164 SCIENCE 1256, 1257 (1969).
69. Calabresi, Reflections on Medical Experimentation in Humans, 98
DAEDALus 387, 391-99 (1969).
70. Havighurst, Compensating Persons Injured in Human Experimenta-
tion, 169 SCIENCE 153 (1970).
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problem of compensation for subjects injured in human experi-
mentation and discuss possible solutions to this problem. 7 1
IV. GENERAL COMMENTS ON FEDERAL REGULATION
Despite these problems, the consensus among investigators and
members of review committees, who are often themselves investi-
gators, is that on balance the current method of operation is a rea-
sonable one. Objective eviden6e to support the effectiveness of the
review procedures as applied nationwide is provided by the fact that
the percentage of problem projects (proposals presenting possible
hazards to subjects and judged unacceptable) among the total pro-
jects involving human subjects declined from 7.4 percent in 1966
(the last year projects were submitted to NIH before the ethical
guidelines were instituted) to 1.7 percent in 1968.72 Nonetheless,
the feeling that more must be done has enjoyed considerable sup-
port.
7 3
The impetus for drafting new law or new regulations affecting
the conduct of human investigation has generally resulted from inci-
dents of flagrant abuse of human rights and extensive publicity of
these incidents. For example, the Nuremberg Code was produced
in response to the horror stories that were revealed at the Nuremberg
war crime trials. The promulgation of the HEW guidelines74 was
in substantial part a result of the New York case in which live cancer
cells were injected into elderly individuals without their knowledge. 75
Most recently, revelations of the Tuskegee syphilis study have in-
spired a new series of laws and regulations. 76 The present regula-
tions,77 which in substantial measure codify the prior HEW guide-
71. For a general discussion of this problem see Adams & Shea-Stonum,
Toward a Theory of Control of Medical Experimentation With Human Sub-
jects: The Role of Compensation, 25 CASE W. Re-s. L. Rlv. 604 (1975).
72. Curran, supra note 65, at 579.
73. Congress has recently passed the National Research Service Award
Act of 1974, Pub. L. No. 94-348, 88 Stat. 342. Two examples of other legisla-
tive proposals that have been introduced are S. 2072, 93d Cong., 1st Sess.
(1973), introduced by Senator Kennedy, and H.R. 10403, 93d Cong., 1st Sess.
(1973), introduced by Representative Rogers. In addition to this legislation,
HEW has promulgated new regulations, 45 C.F.R. §§ 46.1-.22 (1974),
which were recently amended. See note 18 supra. See also Hearings on S.
2071, S. 2072, and H.R. 7724 Before the Subcomm. on Health of the Senate
Comm. on Labor and Public Welfare, 93d Cong., 1st Sess., pt. 4, at 1207-53
(1973).
74. Tim INsTrTuTONAL GUIDE.
75. See note 13 supra and accompanying text.
76. See note 73 supra.
77. 45 C.F.R. §§ 46.1-.22 (1974).
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lines, merit some general observations. These comments are made
from the viewpoint of one investigator who will be subject to the
regulations.
The general tone of the public debate over the regulations con-
firms Edsall's observation that a well-publicized abuse of human
rights leads to an overall reaction that "tends to spiral more and more
tightly into a set of concepts and terms that give emphasis to only
one view of the total situation."78s A component of this "one view"
is the idea that investigators are using human beings.
Whenever this use appears to have been improper, the inves-
tigator is considered to have violated the rights of the indi-
vidual ....
• . . All of these words, phrases, and concepts-even
though they are in themselves -totally correct and admirable
-tend to narrow the framework of thinking in this field and
to force it into a somewhat rigid moralistic-legalistic struc-
.ture based largely upon the risk of individual "violations" of
a code and upon enforcement of the code by an essentially
legalistic system of controls. Such a structure . . . tends
to create and perpetuate a situation in which the investigator
finds himself working in -an atmosphere of supervision and
suspicion.79
Most investigators are already acutely aware that times have changed
and that there has occurred "an abrupt change in public trust and
confidence in the conduct of medical research." 80 A major concern
of investigators is that the emphasis on adversary procedures, in
which the investigators are placed in the position of potential wrong-
doers whose every move must be closely monitored and regulated,
will legitimize the erosion of trust that has occurred. They feel that
there is a need to stress instead the harmonious relationship that must
prevail between researchers and subjects if the public is to continue
to benefit from discoveries in biomedical science.
Closely related to this concern is a widespread feeling that the
development and implementation of greater restrictions and guide-
lines will adversely affect or indeed stifle the remarkable inventive-
ness that has been the pride and accomplishment of the biomedical
research effort in the United States. There are several features of
78. Edsall, A Positive Approach to the Problem of Human Experimenta-
tion, 98 DAEDALUS 463, 464 (1969).
79. id. at 464-65.
80. Chalkley, supra note 64, at 779.
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the regulations that promote this concern. One is the sheer weight
of the bureaucracy which has been proposed -to regulate human ex-
perimentation. Many investigators and review committees are al-
ready of the opinion that the paperwork involved in preparing and
approving acceptable protocols is extensive and taxing. To com-
pound this with even more reports, memoranda, and the like will so
overburden those wishing to undertake research that some, perhaps
many, will conclude that it is simply not worth the trouble to prepare
the required documentation. The consequence of this contraction of
effort will be a marked slowing of the pace of improvement in medi-
cal practice. This result may well be as objectionable to the general
public as their unease with the use of human subjects in research.
Apart from the administrative burdens that inevitably flow from
the implementation of the regulations, the interposition of two or
three more layers of bureaucracy at both the national and the local
levels is unlikely to improve -the review process.81 Rather, like all
other bureaucracies and regulatory agencies, the staffs of -the advisory
committees and groups will feel a need to justify their existence and
demonstrate their effectiveness. The result will be some degree of
harrassment of investigators who are seeking to comply with the law
and a slowing down of the review process so that the time required
to secure approval will increase from one or two months to upwards
of four months. Since the number of identified abuses in clinical
research is so small, especially when considered in relation to the
number of investigators pursuing human experimentation, it will be
difficult if not impossible to demonstrate that the added controls have
produced a detectable decrease in abuses.
Under the provisions of the National Research Service Award
Act of 1974,82 "each entity which applies for a grant or contract un-
der [the] Act for any project or program which involves the conduct
of biomedical or behavioral research involving human subjects" must
establish an institutional review board.88 Although the Act does not
specify the required composition of such boards, existing regulations
require that the board shall -not consist entirely of members of a
single profession or persons affiliated with the parent organization 84
81. Ratnoff, Who Shall Decide When Doctors Disagree? A Review of the
Legal Development of Informed Consent and the Implications of Proposed
Lay Review of Human Experimentation, 25 CASE W. Ras. L. REv. 472 (1975).
82. See National Research Service Award Act of 1974, Pub. L. No. 94-
348, 88 Stat. 342.
83. Id. § 474.
84. 45 C.F.R. §§ 46.6(b) (4), (5) (1974).
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Such requirements could lead to reduction in the number of physician
members. Already nonphysicians on the committees express a sense
of inadequacy regarding their ability to evaluate intelligently some
of the more complex scientific problems submitted for review. The
effect of any restriction on physician membership would be to place
a greater responsibility for scientific review on fewer individuals.
The physician members would either have to spend considerable time
giving their nonmedical colleagues short courses in medicine, or the
latter would simply defer to the physicians and confine their attention
to such issues as the quality of informed consent.
Hitherto, physicians serving on institutional review committees
have done so recognizing that such service is a necessary function
of their positions on the staffs of the sponsoring institutions. They
have never received monetary or other recompense for their time and
effort. It is unrealistic to expect that nonphysicians who are asked
to serve on one or another institutional advisory group and who by
law must have no prior affiliation with the institution will donate
their time. Yet scant attention has been paid to the question of how
the involvement of the representatives of the community will be fi-
nanced. If strict limitations are placed on physician membership,
the costs for maintaining these advisory groups may become very
great.
In response to recommendations put forward by Katz and others
for the establishment of a National Human Investigation Board,85 a
National Commission for the Protection of Human Subjects of Bio-
medical and Behavioral Research was established under the National
Research Service Award Act.86 The Commission is designed to pro-
vide overall direction in the area of policy formulation and to relieve
local institutional committees of the burden of policy formulation in
certain critical and sensitive areas. 87 Nevertheless, the purpose and
85. See Hearings on S. 974, S. 878, and S.J. Res. 71 Before the Subcomm.
on Health of the Senate Comm. on Labor and Public Welfare, 93d Cong., 1st
Sess. 1053 (1973).
86. National Research Service Award Act of 1974, tit. II, pt. A, § 201(a),
Pub. L. No. 94-348, 88 Stat. 342.
87. The purpose of the Commission is to conduct a comprehensive investi-
gation and study to identify the basic ethical principles which should underlie
the conduct of biomedical and behavioral research, evaluate existing guidelines
for the protection of human subjects, and make appropriate recommendations
to the Secretary of HEW concerning further steps, if any, to be taken. Id.
§ 202(a)(1)(A). The duties of the Commission are (1) to identify the
requirements of informed consent for participation by children, prisoners,
and the institutionalized mentally infirm, id. § 202(a)(1)(C)(2); (2) to
determine the need for a mechanism to assure that human subjects not reg-
[Vol. Z5:533
THE REVIEW PROCESS
function of the Commission are not designed to usurp the responsibil-
ities of the local institutional committees in the implementation of
policy, i.e., in the actual review of protocols. It is important that
local committees retain responsibility for implementation of policy
since local committees (1) have the advantage of being most sensi-
tive to local problems and responsive to local conditions, (2) can be
made more readily aware of any violations and can more effectively
monitor continuing compliance with committee decisions, and (3)
provide a mechanism whereby the investigator may become involved
in the problems of ethical research.
Plans for disseminating decisions of local committees, particularly
those made in relation to especially difficult problems, have consider-
able merit.s8 A system for exchanging information would provide
committee members in one area the benefit of experience gained by
committees in other areas and would promote uniformity in decision-
making. Plans for a scheme to compensate subjects injured in the
course of human experimentation also answer a need to provide
greater safeguards for these individuals.8 9 In relation to these, it is
important that laws and regulations make determinations regarding
the legal status of the decisions of review committees and of the pro-
tocols that have been approved through proper application of review
procedures. The liability of both investigators and review commit-
tees has to be defined. Presently, researchers, members of review
ulated by the Secretary are protected, id. § 202(a)(1)(C)(3); (3) to in-
vestigate the nature and extent of research involving living fetuses, the pur-
poses for which such research has been undertaken, and alternative means for
achieving such purposes, id. § 202(b); (4) to investigate the use of psy-
chosurgery during the 5-year period ending December 31, 1972, id. § 202(c);
and (5) to undertake a comprehensive study of ethical, social, and legal impli-
cations of advances in biomedical and behavioral research and study, id. § 203.
The last of these functions is to include an analysis and evaluation of (1)
scientific and technological advances in past, present, and projected biomedical
and behavioral research and services; (2) implications of such advances, both
for individuals and for society; (3) laws and moral and ethical principles gov-
erning the use of technology in medical practice; (4) public understanding of
and attitudes toward such implications and laws and principles; and (5) impli-
cations for public policy of such findings as are made by the Commission with
respect to advances in biomedical and behavioral research and technology and
public attitudes towards such advances. Id. §§ 203(1)-(5). The life of the
Commission ends in 1976, id. § 204(d), when it will be succeeded by the Na-
tional Advisory Council for the Protection of Subjects of Biomedical and Be-
havioral Research. Id. § 211(a), amending 42 U.S.C. § 217(f)(1).
88. Such a proposal is contained in S. 2072, 93d Cong., 1st Sess., § 1208
(1973).
89. Such a plan is advocated in Havighurst, Compensating Persons Injured
in Human Experimentation, 169 ScmNcE 153 (1970).
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committees, patient advocates, and institutions are subject to civil lia-
bility arising out of injuries sustained in the course of research proj-
ects even though they may have complied faithfully with current reg-
ulations. 90 In evaluating claims of injury, courts are free to decide
the issues with the benefit of hindsight. That is, they may apply
standards of practice which may not have existed at the inception
of the project and which indeed may have resulted from the findings
of the project.
V. CONCLUSION
It is reasonable that efforts designed to improve the ethical cli-
mate of human experimentation should redound to the benefit of the
investigator as well as his subjects. Progress in medical science de-
pends on research, much of which requires human experimentation.
Consequently, human experimentation is necessary and proper, and
the researcher involved in such endeavors should not be placed in
jeopardy or penalized for attempting to aid society.9 ' The goal of
the physician engaged in human experimentation, therefore, must be
to proceed in the way that will maximize the benefits to society while
protecting the rights and welfare of the human subjects. By ensuring
that every project is properly designed and executed, a smoothly
functioning institutional review committee can assist the investigator
in achieving this goal.
90. Cady, Forensic Medicine, Medical Malpractice: What About Experi-
mentation, 6 ANNALs OF W. MED. & SURGERY 164 (1952). See Adams &
Shea-Stonum, supra note 71, for a discussion of the liability of a physician for
injury resulting from experimentation.
91. Beecher, supra note 43, at 470.
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